VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Monday morning. The brokerage issued a sell rating on the stock.

Several other analysts also recently commented on VNRX. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a report on Tuesday, December 10th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Down 4.6 %

Shares of VolitionRx stock opened at $0.60 on Monday. The company has a market capitalization of $55.60 million, a P/E ratio of -1.67 and a beta of 1.17. The stock has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.66. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Insider Transactions at VolitionRx

In other news, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock worth $204,212 in the last ninety days. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.